VDyne has announced that the first patient has been enrolled and treated in the TRIVITA US investigational device exemption (IDE) pivotal study of the TriNova transcatheter tricuspid valve replacement (TTVR) system. The randomised controlled study will compare TriNova head-to-head with the commercially available Evoque (Edwards Lifesciences) TTVR system. The prospective, global, multicentre, 1:1 randomised controlled […] The post TriNova TTVR system goes head-to-head with Evoque in randomised trial appeared first on Cardiovascular News .